Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CMR assessment of vericiguat for ventricular remodeling in heart failure with coronary artery disease
ChiCTR2400091136Phase 4Not yet recruiting
- Sponsor
- First Affiliated Hospital of Xi'an Jiaotong University
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial in heart failure (HF) and coronary arteriosclerosis comparing Vericiguat Group with Standard of care Group (2 arms). Primary endpoint: Myocardial extracellular volume (ECV) at 8 months. Planned start Oct 2024; status: not yet recruiting.
02
Drugs
vericiguat
03
Conditions
heart failure (HF)coronary arteriosclerosis
Beyond the preview
Go deeper on ChiCTR2400091136.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400091136.